ARVN

Analyst Note: ARVN (Arvinas, Inc.)

Date: 2026-06-13 Current Price: $7.67

1. Structural Readiness

• Conservative Entry: Not yet defined (requires breakout confirmation).
• Aggressive/Pre-Breakout Entry: $7.67 (Current Price).
• Breakout Level: Not yet defined (requires price to close above the resistance cap of the forming coil).
• Extension: Not applicable (price is within the consolidation range, not extended above the breakout).
• ATR Context: Current ATR is 5.8% (High). This indicates elevated volatility, which is consistent with the "High" bucket (4–6%) and suggests significant price movement potential but also higher risk of whipsaw during the forming phase.

2. Thesis Layer

• Thesis Classification: Tactical / Setup-Led.
• Analysis: As of 2026-06-13, there is no named secular macro thesis driving this specific trade. The investment case is not derived from a broad market rotation or a specific macroeconomic theme (e.g., "AI in Healthcare" or "Global Aging"). Instead, the conviction must be derived entirely from the quality of the technical setup (the forming coil) and the specific, near-term business fundamentals disclosed by management. The name is being judged on its ability to execute its clinical pipeline and maintain liquidity, rather than a secular tailwind.

3. Business Fundamentals

• Company Overview: Arvinas, Inc. is a biopharmaceutical company focused on targeted protein degradation. Its core technology involves heterobifunctional PROTAC degraders, which eliminate disease-causing proteins rather than just inhibiting them.
• Business Model: The company operates in the Healthcare / Biotechnology industry. It generates value through the advancement of its proprietary pipeline from preclinical to clinical stages, with the ultimate goal of commercializing approved therapies.
• Key Evidence (As of 2026-06-13):
• Commercial Milestone: The company has achieved a historic regulatory milestone. As of May 11, 2026, the FDA approved VEPPANU™ (vepdegestrant) for the treatment of adults with ER+/HER2- advanced or metastatic breast cancer with ESR1 mutations. This is the first ever approval of a heterobifunctional PROTAC degrader (Evidence E6, E8, E12).
• Pipeline Progress:
• Parkinson's Disease (PD): Phase 1 data presented at AD/PD 2026 showed approximately 50% or greater reductions in CSF LRRK2 by day 14 (Evidence E4). The company plans to present data from the multiple-dose cohort of ARV-102 in PD in Q1 2026 (Evidence E15).
• PSP (Progressive Supranuclear Palsy): An IND was submitted for ARV-102 in PSP. Management anticipates the U.S. Phase 1b trial will begin in the second half of 2026 (Evidence E2, E9, E10).
• Oncology (KRAS G12D): Enrollment for ARV-806 in KRAS G12D solid tumors initiated in Q2 2025. Dose escalation for once-weekly administration was completed ahead of plan in Q1 2026 (Evidence E5, E16, E17). A Phase 1 trial for ARV-6723 in advanced solid tumors is planned for mid-2026 (Evidence E11).
• Financial Position: As of March 31, 2026, the company held approximately $614.9 million in cash, cash equivalents, and marketable securities. Management guidance states this capital is sufficient to maintain a runway into the second half of 2028 (Evidence E3, E14).
• Clinical Experience: To date, the company has dosed more than 2,000 patients and healthy volunteers using its PROTAC technology (Evidence E7).

4. Archetype and Conviction

• Archetype: Growth Leader.
• *Fit:* The company fits the "Growth Leader" archetype due to its status as the first-in-class commercializer of a novel therapeutic modality (PROTACs) and its aggressive, well-funded pipeline expansion into high-unmet-need areas (PSP, KRAS G12D). The approval of VEPPANU validates the platform, shifting the narrative from pure R&D to commercial execution.
• Valuation & Conviction Stack:
• Thesis Strength: Moderate. The "Tactical" nature means the thesis is binary: success depends on the execution of the 2026-2028 clinical milestones and the commercial uptake of VEPPANU.
• Evidence Quality: High. The evidence base is robust, citing specific FDA approvals, precise clinical data points (50% reduction in LRRK2), and concrete financial runway guidance.
• Rerating Potential: Significant. The transition from a pre-revenue biotech to a company with a commercial product (VEPPANU) and a clear path to new indications (PSP, KRAS) offers a structural rerating opportunity if the forming coil breaks out.
• Conviction: The setup is a partial signal. The business fundamentals are strong (first-in-class approval, ample cash), but the technical setup is not yet "Confirmed." The high volatility (ATR 5.8%) requires careful position sizing if entering pre-breakout.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen: A confirmed breakout above the resistance level of the forming coil. Positive top-line data from the VEPPANU commercial launch or the initiation of the PSP trial ahead of the H2 2026 guidance would strengthen the case.
• Gaps in Evidence:
• Commercial Data: While VEPPANU is approved, there is no specific evidence in the provided block regarding early sales velocity or reimbursement status as of June 2026.
• Specific Financial Guidance: The evidence provides a cash runway date (H2 2028) but does not provide specific revenue guidance or burn rate projections for the remainder of 2026.
• Competitive Landscape: No specific evidence regarding competitive pressures in the ER+ breast cancer or KRAS G12D spaces is provided in the source text.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key risks: High volatility (ATR 5.8%) leading to whipsaw before breakout; Clinical trial delays in PSP or KRAS programs; Lack of commercial sales data to validate revenue ramp; Technical setup remains unconfirmed (Forming, not Active). Sizing hint: Position size should be conservative relative to a confirmed breakout, reflecting the "forming" status and elevated ATR. Expected path: Management expects to initiate PSP trials in H2 2026 and KRAS trials in mid-2026; price likely to consolidate near current levels until a catalyst (trial initiation or data readout) triggers a breakout. Expected horizon: 3 to 6 months for the setup to resolve (breakout or invalidation).